Regulation and Products

Share

In 2009, we won a hard-fought campaign that led to Congress passing a law granting the U.S. Food and Drug Administration (FDA) the authority to regulate all tobacco products, including cigarettes, e-cigarettes, cigars and hookah. Yet, it took the FDA seven years to begin their oversight of many of these products with much more work left to be done. 

Recent spikes in the use of e-cigarettes makes clear that more must be done to regulate tobacco products and the industry's deceptive marketing practices.  We are working to ensure the government fully leverages the regulatory power it now possesses to protect children and adults. 

Tobacco use costs our nation nearly $300 billion in health care and productivity losses each year.

Take Action

Big Win Against Big Tobacco

It's time to end the youth e-cigarette vaping epidemic

We need Congress to choose kids and families over Big Tobacco and the e-cigarette industry.

Latest Updates

April 23, 2020
Maine

Victory in the fight against cancer requires bold new public policies that promote cancer prevention, early detection of cancer, and expand access to quality, affordable health care. Lawmakers make many decisions that impact the lives of Mainers touched by cancer and their leadership is vital to defeating this disease. In

April 17, 2020
Idaho

Idaho’s 2020 legislative session has come to an end. While the American Cancer Society Cancer Action Network (ACS CAN) did not have a major legislative victory during the session, there is certainly a lot of positive news that we can report. The session ended with growing concern about COVID-19 and

February 27, 2020
Oregon

SALEM, Ore.— Cancer patients, survivors and their loved ones convened at the State Capitol today, February 27, for the annual Cancer Action Day at the Capitol, hosted by the American Cancer Society Cancer Action Network (ACS CAN). February is National Cancer Prevention Month and the group spent the day-long event

February 5, 2020
National

The House Energy and Commerce Subcommittee on Oversight and Investigations holds a hearing on e-cigarette use in the United States amid an ongoing youth tobacco epidemic and one day before the US Food and Drug Administration (FDA) is set to begin enforcement of the agency’s weak guidance released in early January that put industry profits above the health of children.

Regulation and Products Resources

The Draft Guidance can be a step forward if it reduces youth access to the flavored products that have contributed so significantly to the problem of youth tobacco use. However, unless strengthened, the Draft Guidance falls short of the forceful action needed to address a public health crisis of this magnitude.

The undersigned organizations, committed to protecting and promoting the public health by reducing the use of tobacco products, respectfully submit comments on the draft guidance, “Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products: Guidance for Industry.

The core interests of the ACS and the ACS CAN are to improve our scientific understanding of electronic cigarettes, or e-cigarettes, and other novel tobacco products, and to maintain robust and effective protections designed to minimize the risks posed to human research subjects. We appreciate the FDA updating its guidance in the use of investigational tobacco products (ITPs).